Alkermes Plc (NASDAQ: ALKS)
Alkermes Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Alkermes Plc Company Info
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
News & Analysis
Alkermes' Q3 Proprietary Sales Soar 18%
The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness relating to its external revenue streams.
Why Alkermes Stock Is Sinking Today
The biotech company's Q3 revenue and earnings looked great, but the results weren't enough to wow investors.
Why Alkermes Stock Is Jumping Today
The drugmaker beat Wall Street's expectations with its Q1 results.
Why Alkermes Stock Blasted 15% Higher Today
The biotech smashed analyst estimates in its final quarter of 2021.
Why Alkermes Stock Is Sinking Today
Johnson & Johnson partly ended two licensing agreements with the company.
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Biogen isn't the only company whose shares should benefit from a breakthrough drug.
Why Shares of Alkermes Rose 18% Last Month
An agreement with an activist investor capped a busy month.
Want to Make Money in Biotech? Do This First
Keeping track of upcoming events is important.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.